NASDAQ:NAGE Niagen Bioscience Q2 2026 Earnings Results & Report $2.63 -0.06 (-2.23%) Closing price 04:00 PM EasternExtended Trading$2.62 0.00 (-0.19%) As of 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Niagen Bioscience met analyst earnings expectations and missed on revenue in its Q2 2026 results, released August 4, 2026. The company reported EPS of $0.01 versus the $0.01 consensus estimate, while revenue of $29.78 million fell short of the $29.95 million estimate by $0.17 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 4, 2026TimeAfter Market Closes Niagen Bioscience EPS ResultsActual EPS$0.01Consensus EPS $0.01Beat/MissMet ExpectationsOne Year Ago EPSN/AEPS Beat Rate6 of last 8 quartersNiagen Bioscience Revenue ResultsActual Revenue$29.78 millionExpected Revenue$29.95 millionBeat/MissMissed by -$170.00 thousandYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile Niagen Bioscience Q2 2026 Earnings FAQ Did Niagen Bioscience beat earnings estimates for Q2 2026? Niagen Bioscience (NASDAQ:NAGE) reported earnings of $0.01 per share for Q2 2026, matching the consensus estimate of $0.01. The report was announced on Tuesday, August 4, 2026. What was Niagen Bioscience's revenue for Q2 2026? Niagen Bioscience reported revenue of $29.78 million for Q2 2026, against a consensus estimate of $29.95 million. Niagen Bioscience Earnings HeadlinesComparing Unicharm (OTCMKTS:UNICY) & Niagen Bioscience (NASDAQ:NAGE)October 10 at 3:45 AM | americanbankingnews.comAndrew Shao, Ph.D., Senior Vice President of Global Regulatory and Scientific Affairs at Niagen Bioscience, Honored with the 2026 Annette Dickinson Trailblazer Award by Radicle ...October 8, 2026 | marketscreener.comMI have publicly predicted six major American crashes, before each one happened.Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.October 12 at 1:00 AM | Weiss Ratings (Ad)Andrew Shao, Ph.D., Senior Vice President of Global Regulatory and Scientific Affairs at Niagen Bioscience, Honored with the 2026 Annette Dickinson Trailblazer Award by Radicle Science and Council for Responsible Nutrition (CRN)October 8, 2026 | businesswire.comAnalysts Offer Insights on Consumer Goods Companies: Niagen Bioscience (NAGE) and Target (TGT)October 6, 2026 | theglobeandmail.comNiagen Bioscience to Present at LD Micro 20th Annual Main EventOctober 6, 2026 | businesswire.comSee More Niagen Bioscience Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Niagen Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Niagen Bioscience and other key companies, straight to your email. Email Address About Niagen BioscienceNiagen Bioscience (NASDAQ:NAGE) is a life sciences company focused on products and technologies designed to support healthy aging and cellular health. The company’s principal technology is nicotinamide riboside (NR), a form of vitamin B3 that serves as a precursor to nicotinamide adenine dinucleotide (NAD+), a coenzyme involved in cellular energy production and other biological processes. The company develops and commercializes NIAGEN-branded NR ingredients for use in dietary supplements, functional foods and beverages, and other consumer health products. Its consumer portfolio includes Tru Niagen, a direct-to-consumer supplement brand, while its ingredient business supplies NIAGEN products to manufacturers and brand partners. The company also supports its products with scientific research, quality testing and intellectual-property licensing. Niagen Bioscience was formerly known as ChromaDex Corporation and has been associated with research and commercialization efforts involving NAD+ biology and NR. Its products are marketed through online channels, retail distribution and commercial partners in the United States and international markets. The company is led by Chief Executive Officer Rob Fried.View Niagen Bioscience ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 5 Retail Picks to Watch as the Holiday Shopping Season NearsMarketBeat Week in Review – 10/05 - 10/09Q3 Earnings Could Blow Past Consensus—Be Ready for What Comes NextDelta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsC.H. Robinson Bets Its AI Story on RXO—But the Market Isn't SoldApplied Digital’s Hidden Moat Could Unlock Massive Upside Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
